BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27372200)

  • 1. Immunotherapy advances in uro-genital malignancies.
    Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
    Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunotherapy revolution in genitourinary malignancies.
    U Gandhy S; Madan RA; Aragon-Ching JB
    Immunotherapy; 2020 Aug; 12(11):819-831. PubMed ID: 32594815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in genitourinary malignancies.
    Mehta K; Patel K; Parikh RA
    J Hematol Oncol; 2017 Apr; 10(1):95. PubMed ID: 28434403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immunotherapies in GU malignancies.
    Drakaki A; McDermott DF
    Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
    Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
    Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Landscape of Immunotherapy in Genitourinary Malignancies.
    Alhalabi O; Rafei H; Bilen MA; Shah AY
    Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for the Treatment of Urothelial Carcinoma.
    Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
    J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for genitourinary cancer: state of the art and new perspectives.
    Cattrini C; Dellepiane C; Cavo A; Buzzatti G; Tolomeo F; Messina C; Boccardo F
    Anticancer Drugs; 2016 Aug; 27(7):585-99. PubMed ID: 27183027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
    Bigot F; Bonnet C; Massard C
    Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
    Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
    Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunotherapy combinations for genitourinary cancers.
    Al Harthy M; Redman J; Madan RA
    Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in genitourinary malignancies.
    Wattenberg MM; Fong L; Madan RA; Gulley JL
    Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in genitourinary malignancies.
    Thana M; Wood L
    Curr Oncol; 2020 Apr; 27(Suppl 2):S69-S77. PubMed ID: 32368176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy in genitourinary malignancies.
    Hoffman-Censits J; Wilde L
    Curr Opin Urol; 2016 Nov; 26(6):523-8. PubMed ID: 27517637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.
    Shao Z; Wang AZ; George DJ; Zhang T
    Asian J Urol; 2016 Oct; 3(4):268-277. PubMed ID: 29264195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.